Rapid manufactured CAR-T cells enriched for CD45RA-negative T cells exhibit superior persistence compared to conventional CAR-T therapy. Pei X, Lv M, Zhao X, Liu Z, et al. Cancer Lett 2026;661:218865.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pei X, Lv M, Zhao X, Liu Z, et al. Rapid manufactured CAR-T cells enriched for CD45RA-negative T cells exhibit superior persistence compared to conventional CAR-T therapy. Cancer Lett 2026;661:218865.
PMID: 42826832